Proceedings · Session S-925 · filed November 17, 2026

Lab Technology & MethodsSession paper

Evox Builds Potency Assay for Extracellular Vesicle Pipeline

Evox Therapeutics has pre-qualified and QC-transferred a potency assay for its EV gene therapy products, targeting full qualification in a first-in-human study next year.

By Tom Whitfield3 min read663 words

Summary

  • Evox has pre-qualified a potency assay and transferred it into a QC laboratory.
  • Full qualification is planned during a first-in-human study next year.
  • The assay uses an immortalized adherent cell line and a Jess Simple Western readout.
  • Gavin warns 50-assay batch panels could consume 50% of a batch in low-yield gene therapy manufacturing.
  • The assay is intended to adapt to multiple pipeline products and commercial batch QC.
Extracellular Vesicle Product Developer Creates Potency Assay
FigureExtracellular Vesicle Product Developer Creates Potency Assay — Vector8DIY / pixabay

Evox Therapeutics has pre-qualified a potency assay for its extracellular vesicle (EV)-based gene therapy products and transferred it into a quality control laboratory, with full qualification targeted during a planned first-in-human study next year. The Oxford-based developer wants the same assay to serve multiple pipeline candidates and, eventually, commercial batch release.

The milestone lands early in a field where potency testing often arrives late. Rebecca Gavin, PhD, chemistry, manufacturing, and controls (CMC) director at Evox, says the company deliberately refused to defer the work.

"Sometimes CMC can get kicked down the road a little, with people thinking they'll worry about it later when they have more funding, so [the fact] that we've developed one already is something we're really proud of," Gavin said.

Why EV potency assays are hard

Evox's product encapsulates a ribonucleoprotein (RNP) inside an EV, which acts as the delivery vehicle. The RNP couples to a guide RNA that targets a specific gene, with the aim of reducing production of the protein that gene encodes, Gavin explains.

That architecture invites hard questions. Does the EV get taken up by the cell? Does the editing machinery reach the nucleus? Chasing every one of them, Gavin argues, pushes developers toward over-characterization and over-testing — a trap that bites hardest in gene therapy.

"Our product is quite complex, and that's why people often struggle to develop a potency assay," Gavin said.

"You don't want to have a batch release assay panel that's 50 assays long, where you're having to measure and quantify every aspect of a complex product, and need to dedicate 50% of your batch to testing, especially in the gene therapy field where batch yields are already tricky," she explained.

What the assay actually measures

Evox's answer was to collapse the question set into one functional readout. The assay measures potency directly — demonstrating that the product assembles correctly and reaches its target inside a cell, without enumerating every intermediate step.

The workflow, as Gavin describes it:

  • Dose the EV product onto an immortalized adherent cell line at multiple concentrations
  • Let the cells grow for a period
  • Test cell lysates on a Jess Simple Western system
  • Fit a dose-response curve from the quantitative readout

"We get a very specific quantitative readout, and that allows us to determine a dose-response curve, which shows how active our product is at reducing our protein of interest," Gavin said.

The Jess system, a capillary-based Western blot platform from ProteinSimple, replaces gel electrophoresis with an automated workflow — relevant for QC labs that need reproducible quantitative output rather than qualitative bands.

What remains unproven

The measured result so far is pre-qualification plus a QC lab transfer. Full qualification is still ahead and depends on the first-in-human study planned for next year. Commercial use as a batch release assay is a further projection, not a completed milestone, and adaptation to additional pipeline products remains a goal the company has stated but not yet demonstrated.

The company has not disclosed which product leads the assay will support first, nor the identity of the protein of interest or the target gene. Those details will matter to CMC teams benchmarking their own EV programs against Evox's timeline.

The portfolio logic

For R&D managers, the case study carries a budget argument. A single functional assay that transfers across products avoids the 50-assay panel Gavin warns about — and the 50% batch consumption that comes with it. In gene therapy, where manufacturing yields are characteristically tight, conserving batch volume for testing versus dose supply is a real trade-off.

The approach also front-loads regulatory risk. Developers that defer potency assays until regulators ask, Gavin suggests, face harder questions later. Evox's assay enters its first-in-human study next year already pre-qualified, positioned for full qualification during the trial and reuse across future EV-based candidates in commercial production.

via Genetic Engineering & Biotechnology News (Source)

Filed under

  • extracellular-vesicles
  • potency-assays
  • gene-therapy
  • cmc
  • quality-control
Share this article:

More from Tom Whitfield

Tom Whitfield

Show full bio

Senior reporter covering technology and product news in research and development at Hypothesis Wire.

268 articles

References

  1. WHO's 15-Partner mRNA Programme Tests the Industry's Manufacturing Playbook
  2. Delivery Vehicles, Not Payloads, Will Decide CGT Success, USP Scientist Argues
  3. Stable Pools Move Biologics Off the Clone-First Path
  4. 66% to 90%: The Outsourcing Numbers Driving CGT Contracting
  5. Stem cell entrepreneurs lobby FDA for regulatory path, citing peptide precedent

« Previous articleNext article »